SUR180 THERAPEUTICS, INC.

Mcallen, TX · Biotech · Private

CRHR1 antagonist small molecule therapeutic for endometriosis

sur180therapeutics.com →
Grants
$3.1M
5 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · Repurposing CRH antagonists for the treatment of endometriosis$299,864
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · Repurposing CRH antagonists for the treatment of endometriosis$371,036
Federal grantDepartment of Health and Human Services · Phase I · Repurposing CRH antagonists for the treatment of endometriosis$71,172
Federal grantDepartment of Health and Human Services · Phase II · Phase II- Repurposing CRH antagonists for the treatment of endometriosis$1,239,987
Federal grantDepartment of Health and Human Services · Phase II · Phase II- Repurposing CRH antagonists for the treatment of endometriosis$1,140,501
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3108ERNEST PHARMACEUTICALS LLC——
3109MECHASIM INC.——
3110ESCAZYME BIOCHEMICALS, LLC——
3111SUR180 THERAPEUTICS, INC.——
3112Cybrexa, Inc.——
3113GENERAL BIOLOGICS, INC.——
3114MONOMERCHEM, inc——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.